Cross-ancestry polygenic risk score now offered with the Empower™ hereditary cancer test AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NTRA) (NASDAQ: NTRA), a global leader in cell-free DNA and ...

MyOme’s Rare Disease diagnostic product addresses these challenges by providing a more comprehensive WGS-based approach, promoting efficient and accurate diagnosis, leading to improved patient ...

New whole-genome test uncovers hidden genetic risk beyond traditional screening, empowering earlier and more precise care for millions of men. MENLO PARK, Calif., Nov. 20, 2025 /PRNewswire/ -- MyOme, ...

MENLO PARK, Calif. and CINCINNATI, Dec. 3, 2025 /PRNewswire/ -- MyOme, a leading clinical whole-genome testing and polygenic risk modelling (PRS) company, today announced a strategic partnership with ...

With a single genome from a single sample, we can now deliver insights that deepen with every scientific advance—empowering patients and providers in a way narrower testing simply cannot" said Dr.

Empowering employees with actionable genetic insights to prevent disease and improve long-term health outcomes. MENLO PARK, Calif., Jan. 30, 2025 /PRNewswire/ -- MyOme, a leading clinical innovation ...

MyOme, Inc., a leading clinical genetics innovation company, and Broad Clinical Labs (BCL), the world expert in whole genome sequencing (WGS) are announcing a partnership to support the Southern ...

Partnership unites Illumina's leading sequencing technology with cutting-edge clinical genomics analyses and AI to advance precision medicine for early detection and prevention. The U.S. spends ...

The MarketWatch News Department was not involved in the creation of this content. MENLO PARK, Calif., Sept. 3, 2025 /PRNewswire/ -- MyOme, a leading clinical whole genome testing and polygenic risk ...

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, and MyOme, a leading clinical whole genome analysis and polygenic risk modeling ...